Biomarkers for immunotherapy in urological cancers

被引：1

作者：

Gust, Kilian M. ^{[1
]}

Resch, Irene ^{[1
]}

D'Andrea, David ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Urol, Comprehens Canc Ctr, Waehringer Guertel, Austria

来源：

CURRENT OPINION IN UROLOGY | 2018年 / 28卷 / 01期

关键词：

checkpoint inhibition; renal cell carcinoma; urothelial carcinoma; METASTATIC UROTHELIAL CARCINOMA; SINGLE-ARM; MULTICENTER; NIVOLUMAB; THERAPY;

D O I：

10.1097/MOU.0000000000000465

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of review Immunotherapies for urological malignancies have made tremendous progress by targeting immune checkpoints and have been implemented in clinical practice nowadays. Though siginifcant number of patients does not respond to immunotherapy. Biomarkers could help to predict response to treatment, but are still under investigation. We reviewed the literature to identify relevant biomarkers in patient treated with immunotherapy. Recent findings A comprehensive search of PubMed through has been performed to identify important relevant publications from 2016 to 2017 on biomarkers for immunotherapies in urological cancers including reported clinical trials. In addition, abstracts of relevant oncological scientific meetings from 2017 have been implemented. Summary Checkpoint inhibitors have shown substantial improvement in the treatment of metastatic RCC and metastatic and locally advanced urothelial cancer. There is an unmet need for the development of predictive biomarkers in order to identify patients who are more likely to respond to therapy.

引用

页码：25 / 28

页数：4

共 16 条

[1] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[2] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[3] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[4] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[5]

Escudier B, 2017, CHECKMATE 214 EFFICA

[6] CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [J].

Escudier, Bernard ;

Sharma, Padmanee ;

McDermott, David F. ;

George, Saby ;

Hammers, Hans J. ;

Srinivas, Sandhya ;

Tykodi, Scott S. ;

Sosman, Jeffrey A. ;

Procopio, Giuseppe ;

Plimack, Elizabeth R. ;

Castellano, Daniel ;

Gurney, Howard ;

Donskov, Frede ;

Peltola, Katriina ;

Wagstaff, John ;

Gauler, Thomas C. ;

Ueda, Takeshi ;

Zhao, Huanyu ;

Waxman, Ian M. ;

Motzer, Robert J. .

EUROPEAN UROLOGY, 2017, 72 (06) :962-971

[7] Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. [J].

Iyer, Gopa ;

Audenet, Francois ;

Middha, Sumit ;

Carlo, Maria Isabel ;

Regazzi, Ashley Marie ;

Funt, Samuel ;

Al-Ahmadie, Hikmat ;

Solit, David B. ;

Rosenberg, Jonathan E. ;

Bajorin, Dean F. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[8] Gene-expression profiling to predict responsiveness to immunotherapy [J].

Jamieson, N. B. ;

Maker, A. V. .

CANCER GENE THERAPY, 2017, 24 (03) :134-140

[9] Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer [J].

Massard, Christophe ;

Gordon, Michael S. ;

Sharma, Sunil ;

Rafii, Saeed ;

Wainberg, Zev A. ;

Luke, Jason ;

Curiel, Tyler J. ;

Colon-Otero, Gerardo ;

Hamid, Omid ;

Sanborn, Rachel E. ;

O'Donnell, Peter H. ;

Drakaki, Alexandra ;

Tan, Winston ;

Kurland, John F. ;

Rebelatto, Marlon C. ;

Jin, Xiaoping ;

Blake-Haskins, John A. ;

Gupta, Ashok ;

Segal, Neil H. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26) :3119-+

[10] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial [J].

Motzer, Robert J. ;

Rini, Brian I. ;

McDermott, David F. ;

Redman, Bruce G. ;

Kuzel, Timothy M. ;

Harrison, Michael R. ;

Vaishampayan, Ulka N. ;

Drabkin, Harry A. ;

George, Saby ;

Logan, Theodore F. ;

Margolin, Kim A. ;

Plimack, Elizabeth R. ;

Lambert, Alexandre M. ;

Waxman, Ian M. ;

Hammers, Hans J. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) :1430-1437

← 1 2 →